argenex (NASDAQ:ARGX) Price Target Raised to $1,182.00

argenex (NASDAQ:ARGX) had its target price increased by Citigroup from $1,152.00 to $1,182.00 in a research report released on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research analysts also recently issued reports on the stock. Morgan Stanley lifted their price objective on shares of argenex from $1,170.00 to $1,180.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Bank of America increased their target price on shares of argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a research report on Thursday, July 2nd. Royal Bank Of Canada raised their target price on shares of argenex from $890.00 to $945.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Guggenheim lifted their price target on shares of argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $940.00 price target on shares of argenex in a research report on Thursday, June 25th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, argenex has an average rating of “Moderate Buy” and a consensus target price of $1,042.67.

argenex Price Performance

Shares of ARGX stock opened at $924.60 on Tuesday. The stock’s 50-day moving average is $865.90 and its 200 day moving average is $814.39. argenex has a 1-year low of $577.04 and a 1-year high of $953.58. The company has a market cap of $57.84 billion, a P/E ratio of 41.17, a PEG ratio of 1.05 and a beta of 0.45.

argenex (NASDAQ:ARGX) last announced its earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, topping analysts’ consensus estimates of $5.86 by $1.46. The business had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.45 billion. argenex had a net margin of 31.31% and a return on equity of 44.37%. On average, analysts anticipate that argenex will post 26.27 EPS for the current year.

Hedge Funds Weigh In On argenex

Several hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC increased its stake in argenex by 32.1% during the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after purchasing an additional 122 shares in the last quarter. NewEdge Advisors LLC lifted its stake in shares of argenex by 5,962.5% during the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after buying an additional 1,431 shares during the period. Focus Partners Wealth lifted its stake in shares of argenex by 22.3% during the first quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after buying an additional 73 shares during the period. Geneos Wealth Management Inc. grew its holdings in shares of argenex by 550.0% during the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after buying an additional 99 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in shares of argenex by 60.2% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock valued at $73,000 after buying an additional 50 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported Q2 2026 EPS of $7.32, ahead of consensus at $5.86, and revenue of $1.54 billion versus expectations of $1.45 billion, reinforcing the view that execution remains strong. argenx earnings report and conference call
• Positive Sentiment: Global Vyvgart sales jumped sharply in the second quarter, with one report citing about 60% growth year over year, signaling accelerating demand for argenx’s lead product. Reuters article on Vyvgart sales jump
• Positive Sentiment: The company’s half-year 2026 results and business update point to continued commercial progress and a supportive backdrop as additional pipeline readouts approach. Half-year 2026 financial results and business update
• Positive Sentiment: Guggenheim reiterated a Buy rating, adding to the bullish sentiment around the stock after the earnings release. Guggenheim Buy rating article
• Neutral Sentiment: Investors are also focusing on the Q2 earnings call transcript and related coverage for more detail on management’s outlook, pipeline timing, and launch execution. Q2 2026 earnings call transcript

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.